A year of TIGIT (and Alzheimer’s) for Roche

Two years after kicking off Tigit mania with the start of nine pivotal studies of its contender, tiragolumab, Roche will find out whether its bet has been worth it. 2022 will be the year that four of these studies yield data, the Swiss company told investors today.